Novartis receives FDA approval for Signifor LAR to treat acromegaly

Swiss drugmaker Novartis has received approval from US Food and Drug Administration (FDA) for its Signifor long-acting release LAR (pasireotide) for injectable suspension and intramuscular use to treat patients with acromegaly.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news

Related Links:

ConclusionsPDP should be considered as a differential diagnosis when a patient presents with hypertrophic osteoarthropathy and acromegalic features.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Authors: Kan S, Kizilgul M, Celik B, Beysel S, Caliskan M, Apaydin M, Ucan B, Cakal E Abstract Nodular thyroid disease is a very common disorder in patients with acromegaly. Insulin-like growth factor-1 (IGF-1) is a thyroid growth factor, and there is a correlation between IGF-1 levels and thyroid volume (TV) in patients with acromegaly. There is no study investigating the impact of somatostatin analog (SSA) treatment on thyroid nodule volume in patients with acromegaly. We aimed to assess thyroid nodule volume change with SSA treatment in patients with persistent acromegaly. We retrospectively analyzed data from 1...
Source: Endocrine Journal - Category: Endocrinology Tags: Endocr J Source Type: research
ConclusionsPatient adherence to pegvisomant was high (60.7 –92.1%), but more than a third of the patients in the study made mistakes during the administration process, with a potential impact on disease control. Besides dosing compliance, correct administration of medication should be carefully assessed in these patients.
Source: Pituitary - Category: Endocrinology Source Type: research
Source: eMedicineHealth.com - Category: General Medicine Source Type: news
Publication date: Available online 10 February 2019Source: Molecular Phylogenetics and EvolutionAuthor(s): Michael Knapp, Jessica E. Thomas, James Haile, Stefan Prost, Simon Y.W. Ho, Nicolas Dussex, Sophia Cameron-Christie, Olga Kardailsky, Ross Barnett, Michael Bunce, M. Thomas P. Gilbert, R. Paul ScofieldAbstractPrior to human arrival in the 13th century, two large birds of prey were the top predators in New Zealand. In the absence of non-volant mammals, the extinct Haast's eagle (Hieraaetus moorei), the largest eagle in the world, and the extinct Eyles' harrier (Circus teauteensis) the largest harrier in the world, had ...
Source: Molecular Phylogenetics and Evolution - Category: Molecular Biology Source Type: research
CONCLUSIONS: Coexistence of acromegaly and numerous other tumors suggests a common etiology of these disorders. However, no genetic abnormality could be identified with the tests that have been performed. PMID: 30742299 [PubMed - as supplied by publisher]
Source: Endokrynologia Polska - Category: Endocrinology Authors: Tags: Endokrynol Pol Source Type: research
Authors: Pico A Abstract PMID: 30732428 [PubMed - as supplied by publisher]
Source: Minerva Endocrinologica - Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
Presenting an integrated case discussion on acromegaly in DAMS Unplugged series.Famous Radiology Blog http://www.sumerdoc.blogspot.com TeleRad Providers at www.teleradproviders.com Mail us at sales@teleradproviders.com
Source: Sumer's Radiology Site - Category: Radiology Authors: Source Type: blogs
aù F Abstract The GH-receptor antagonist pegvisomant (PEG) reduces peripheral IGF-1 synthesis and is used to treat acromegaly patients resistant or intolerant to somatostatin analogues (SSA). Medical therapy is generally life-long in patients with acromegaly, since disease remission is very uncommon after SSA discontinuation and has never been reported after PEG withdrawal. Here, we report for the first time the cases of two acromegaly patients treated with PEG monotherapy for many years because of resistance to SSA, who persistently maintained normal serum IGF-1 levels after PEG withdrawal. The first patie...
Source: Growth Hormone and IGF Research - Category: Endocrinology Authors: Tags: Growth Horm IGF Res Source Type: research
Authors: Chanson P, Vialon M, Caron P Abstract INTRODUCTION: As pregnancy is rare in women with acromegaly, only case reports and few series have been published. Areas covered: All case reports and publications dealing with pregnancy in patients with acromegaly were collated. Information concerning the effects of acromegaly on pregnancy outcomes, the impact of pregnancy on GH/IGF-I measurements, acromegaly comorbidity and pituitary adenoma size, the effects of treatment of acromegaly on fetus outcomes were retrieved and analyzed. Expert commentary: Based on the small number of reported cases, pregnancy is generally...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
More News: Acromegaly | Food and Drug Administration (FDA) | Pharmaceuticals